Published in Am J Hum Genet on August 01, 2007
Genetic analysis of human traits in vitro: drug response and gene expression in lymphoblastoid cell lines. PLoS Genet (2008) 5.08
Genetic architecture of transcript-level variation in humans. Am J Hum Genet (2008) 3.36
Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc Natl Acad Sci U S A (2010) 2.43
The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin Pharmacol Ther (2013) 2.40
Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA (2015) 2.20
Pharmacogenomic discovery using cell-based models. Pharmacol Rev (2009) 1.96
Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst (2010) 1.76
The effects of EBV transformation on gene expression levels and methylation profiles. Hum Mol Genet (2011) 1.74
The HapMap Resource is Providing New Insights into Ourselves and its Application to Pharmacogenomics. Bioinform Biol Insights (2008) 1.73
Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans. Mol Cancer Ther (2008) 1.67
Heritable and non-genetic factors as variables of pharmacologic phenotypes in lymphoblastoid cell lines. Pharmacogenomics J (2010) 1.66
Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res (2008) 1.59
Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res (2008) 1.57
Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res (2009) 1.48
Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res (2011) 1.47
Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood (2008) 1.46
Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin (2009) 1.39
Genetic architecture of microRNA expression: implications for the transcriptome and complex traits. Am J Hum Genet (2012) 1.36
Pharmacogenomic characterization of US FDA-approved cytotoxic drugs. Pharmacogenomics (2011) 1.34
Population differences in microRNA expression and biological implications. RNA Biol (2011) 1.33
Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy. Clin Cancer Res (2011) 1.32
PACdb: a database for cell-based pharmacogenomics. Pharmacogenet Genomics (2010) 1.28
Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. J Natl Cancer Inst (2011) 1.27
Identification of genomic regions contributing to etoposide-induced cytotoxicity. Hum Genet (2008) 1.26
Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis. Pharmacogenet Genomics (2008) 1.26
Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Transl Res (2011) 1.22
Beyond the HapMap Genotypic Data: Prospects of Deep Resequencing Projects. Curr Bioinform (2008) 1.19
Integrating Epigenomics into Pharmacogenomic Studies. Pharmgenomics Pers Med (2008) 1.18
Data-driven methods to discover molecular determinants of serious adverse drug events. Clin Pharmacol Ther (2009) 1.17
Genome-wide analysis correlates Ayurveda Prakriti. Sci Rep (2015) 1.14
Genome-wide association study of d-amphetamine response in healthy volunteers identifies putative associations, including cadherin 13 (CDH13). PLoS One (2012) 1.14
Impact of the 1000 genomes project on the next wave of pharmacogenomic discovery. Pharmacogenomics (2010) 1.12
FstSNP-HapMap3: a database of SNPs with high population differentiation for HapMap3. Bioinformation (2008) 1.12
Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J (2011) 1.09
Mixed effects modeling of proliferation rates in cell-based models: consequence for pharmacogenomics and cancer. PLoS Genet (2012) 1.08
Identification of genetic variants and gene expression relationships associated with pharmacogenes in humans. Pharmacogenet Genomics (2008) 1.06
An exponential combination procedure for set-based association tests in sequencing studies. Am J Hum Genet (2012) 1.05
Whole-genome approach implicates CD44 in cellular resistance to carboplatin. Hum Genomics (2009) 1.04
A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity. Leukemia (2010) 1.03
Association of IRF5 polymorphisms with activation of the interferon alpha pathway. Ann Rheum Dis (2009) 1.02
Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients. PLoS One (2012) 0.99
Identifying genetic variants that contribute to chemotherapy-induced cytotoxicity. Pharmacogenomics (2007) 0.99
Genome-wide local ancestry approach identifies genes and variants associated with chemotherapeutic susceptibility in African Americans. PLoS One (2011) 0.99
Exon-specific QTLs skew the inferred distribution of expression QTLs detected using gene expression array data. PLoS One (2012) 0.98
Population differences in platinum toxicity as a means to identify novel genetic susceptibility variants. Pharmacogenet Genomics (2010) 0.97
Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opin Drug Metab Toxicol (2009) 0.97
Identification of quantitative trait loci underlying proteome variation in human lymphoblastoid cells. Mol Cell Proteomics (2010) 0.97
Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studies. Pharmacogenet Genomics (2011) 0.96
ATHENA: a tool for meta-dimensional analysis applied to genotypes and gene expression data to predict HDL cholesterol levels. Pac Symp Biocomput (2013) 0.95
Knowledge-based data analysis comes of age. Brief Bioinform (2009) 0.95
Copy number polymorphisms and anticancer pharmacogenomics. Genome Biol (2011) 0.93
Use of cell lines in the investigation of pharmacogenetic loci. Curr Pharm Des (2009) 0.93
Comprehensive survey of SNPs in the Affymetrix exon array using the 1000 Genomes dataset. PLoS One (2010) 0.92
Pharmacogenomics of cisplatin-induced ototoxicity. Pharmacogenomics (2011) 0.92
Pharmacogene regulatory elements: from discovery to applications. Genome Med (2012) 0.91
Identification of novel germline polymorphisms governing capecitabine sensitivity. Cancer (2012) 0.89
Discovery and functional assessment of gene variants in the vascular endothelial growth factor pathway. Hum Mutat (2013) 0.89
Expression and alternative splicing of folate pathway genes in HapMap lymphoblastoid cell lines. Pharmacogenomics (2009) 0.89
Co-administration of cisplatin and furosemide causes rapid and massive loss of cochlear hair cells in mice. Neurotox Res (2011) 0.88
Genetic variation that predicts platinum sensitivity reveals the role of miR-193b* in chemotherapeutic susceptibility. Mol Cancer Ther (2012) 0.88
Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity. Trends Cancer Res (2008) 0.87
Genome-wide approaches in pharmacogenomics: heritability estimation and pharmacoethnicity as primary challenges. Pharmacogenomics (2012) 0.87
Ancestry-related differences in gene expression: findings may enhance understanding of health disparities between populations. Pharmacogenomics (2008) 0.87
Genome-wide discovery of genetic variants affecting tamoxifen sensitivity and their clinical and functional validation. Ann Oncol (2013) 0.86
Prediction of individual response to anticancer therapy: historical and future perspectives. Cell Mol Life Sci (2014) 0.86
Expression quantitative trait analyses to identify causal genetic variants for type 2 diabetes susceptibility. World J Diabetes (2014) 0.85
Integrative genomics: quantifying significance of phenotype-genotype relationships from multiple sources of high-throughput data. Front Genet (2013) 0.85
The emerging role of microRNAs in drug responses. Curr Opin Mol Ther (2010) 0.85
The use of genomic information to optimize cancer chemotherapy. Semin Oncol (2011) 0.84
Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patients. Clin Pharmacol Ther (2014) 0.84
Genetic and epigenetic variants contributing to clofarabine cytotoxicity. Hum Mol Genet (2013) 0.84
Integrating heterogeneous high-throughput data for meta-dimensional pharmacogenomics and disease-related studies. Pharmacogenomics (2012) 0.84
Bioinformatic Resources of microRNA Sequences, Gene Targets, and Genetic Variation. Front Genet (2012) 0.84
Protein quantitative trait loci identify novel candidates modulating cellular response to chemotherapy. PLoS Genet (2014) 0.83
An eQTL-based method identifies CTTN and ZMAT3 as pemetrexed susceptibility markers. Hum Mol Genet (2011) 0.83
Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nat Genet (2015) 0.83
Discovery of regulatory elements in human ATP-binding cassette transporters through expression quantitative trait mapping. Pharmacogenomics J (2011) 0.82
Characterization of the colorectal cancer-associated enhancer MYC-335 at 8q24: the role of rs67491583. Cancer Genet (2012) 0.82
Liver expression quantitative trait loci: a foundation for pharmacogenomic research. Front Genet (2012) 0.82
Genomics: applications in mechanism elucidation. Adv Drug Deliv Rev (2008) 0.81
Integrative analyses of genetic variation, epigenetic regulation, and the transcriptome to elucidate the biology of platinum sensitivity. BMC Genomics (2014) 0.80
Concordant gene expression in leukemia cells and normal leukocytes is associated with germline cis-SNPs. PLoS One (2008) 0.80
Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. Clin Cancer Res (2015) 0.79
The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds. Cancer Chemother Pharmacol (2008) 0.79
In vitro human cell line models to predict clinical response to anticancer drugs. Pharmacogenomics (2015) 0.79
EPS8 inhibition increases cisplatin sensitivity in lung cancer cells. PLoS One (2013) 0.78
Functional consequences of PRPF39 on distant genes and cisplatin sensitivity. Hum Mol Genet (2012) 0.78
The association between the T309G polymorphism of the MDM2 gene and sensitivity to anticancer drug is dependent on the p53 mutational status in cellular models. Br J Cancer (2009) 0.78
Genome-wide identification of possible methylation markers chemosensitive to targeted regimens in colorectal cancers. J Cancer Res Clin Oncol (2011) 0.78
Polymorphic variation in TPMT is the principal determinant of TPMT phenotype: a meta-analysis of three genome-wide association studies. Clin Pharmacol Ther (2016) 0.78
Approaches to the discovery of pharmacogenomic markers in oncology: 2000-2010-2020. Pharmacogenomics (2010) 0.78
Lymphoblastoid cell lines models of drug response: successes and lessons from this pharmacogenomic model. Curr Mol Med (2014) 0.77
Heat shock protein-mediated protection against Cisplatin-induced hair cell death. J Assoc Res Otolaryngol (2014) 0.77
Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer. Clin Genitourin Cancer (2016) 0.76
Theory on the coupled stochastic dynamics of transcription and splice-site recognition. PLoS Comput Biol (2012) 0.76
Integrative "omic" analysis for tamoxifen sensitivity through cell based models. PLoS One (2014) 0.75
Comprehensive evaluation of the contribution of X chromosome genes to platinum sensitivity. Mol Cancer Ther (2011) 0.75
Unsupervised assessment of microarray data quality using a Gaussian mixture model. BMC Bioinformatics (2009) 0.75
Computational discovery of transcription factors associated with drug response. Pharmacogenomics J (2015) 0.75
HapMap filter 1.0: a tool to preprocess the HapMap genotypic data for association studies. Bioinformation (2008) 0.75
A haplotype map of the human genome. Nature (2005) 105.70
Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics (2003) 100.88
A general test of association for quantitative traits in nuclear families. Am J Hum Genet (2000) 22.45
Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene (2003) 10.74
Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov (2005) 9.47
Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol (2002) 6.68
Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs (2003) 2.35
Nek2A kinase stimulates centrosome disjunction and is required for formation of bipolar mitotic spindles. Mol Biol Cell (2003) 2.30
Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol (2005) 2.16
Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res (2004) 2.10
Effect of population and gender on chemotherapeutic agent-induced cytotoxicity. Mol Cancer Ther (2007) 2.05
Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res (2004) 1.91
Curing metastatic cancer: lessons from testicular germ-cell tumours. Nat Rev Cancer (2003) 1.65
Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res (2005) 1.36
Small-molecule c-Myc inhibitor, 10058-F4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells. Anticancer Drugs (2007) 1.33
A p53-dominant transcriptional response to cisplatin in testicular germ cell tumor-derived human embryonal carcinoma. Oncogene (2005) 1.28
Inhibition of centrosome separation after DNA damage: a role for Nek2. Radiat Res (2004) 1.18
Cisplatin damage: are DNA repair proteins saviors or traitors to the cell? Chembiochem (2005) 1.18
Cisplatin nephrotoxicity: experimental and clinical studies. Dan Med Bull (1990) 1.16
Live cell imaging reveals distinct roles in cell cycle regulation for Nek2A and Nek2B. Biochim Biophys Acta (2005) 1.11
Ototoxicity: bioprotective mechanisms. Curr Opin Otolaryngol Head Neck Surg (2003) 1.05
Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome. Int J Clin Oncol (2003) 0.96
Role of GADD34 in modulation of cisplatin cytotoxicity. Biochem Pharmacol (2005) 0.95
The role of Polo-like kinase 1 in the inhibition of centrosome separation after ionizing radiation. J Biol Chem (2005) 0.94
Analysis of differential protein expression by cisplatin treatment in cervical carcinoma cells. Int J Gynecol Cancer (2006) 0.91
Relation between cytokine promoter gene polymorphism and toxicity of 5-fluorouracil plus cisplatin chemotherapy. Oncol Rep (2006) 0.89
Platinum-based chemotherapy in metastatic breast cancer: the Leicester (U.K.) experience. Clin Oncol (R Coll Radiol) (2005) 0.89
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet (2008) 30.20
A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science (2006) 27.49
HITS-CLIP yields genome-wide insights into brain alternative RNA processing. Nature (2008) 14.17
Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet (2010) 10.75
Direct detection of DNA methylation during single-molecule, real-time sequencing. Nat Methods (2010) 9.75
SCAN: SNP and copy number annotation. Bioinformatics (2009) 5.96
Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array. BMC Genomics (2006) 5.59
Discovery of tissue-specific exons using comprehensive human exon microarrays. Genome Biol (2007) 5.53
Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev (2006) 5.08
Ultraconserved elements are associated with homeostatic control of splicing regulators by alternative splicing and nonsense-mediated decay. Genes Dev (2007) 4.75
Unusual intron conservation near tissue-regulated exons found by splicing microarrays. PLoS Comput Biol (2006) 4.63
A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci U S A (2007) 4.35
Evaluation of genetic variation contributing to differences in gene expression between populations. Am J Hum Genet (2008) 4.01
Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet (2009) 3.82
Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat Genet (2009) 3.65
Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci U S A (2007) 3.59
Frequency of failure to inform patients of clinically significant outpatient test results. Arch Intern Med (2009) 3.55
Genome-wide mapping of methylated adenine residues in pathogenic Escherichia coli using single-molecule real-time sequencing. Nat Biotechnol (2012) 3.39
Genetic architecture of transcript-level variation in humans. Am J Hum Genet (2008) 3.36
Detection and measurement of alternative splicing using splicing-sensitive microarrays. Methods (2005) 3.21
The methylomes of six bacteria. Nucleic Acids Res (2012) 3.19
Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy. Nat Struct Mol Biol (2010) 3.07
Heritability of alternative splicing in the human genome. Genome Res (2007) 2.76
Mouse models of human AML accurately predict chemotherapy response. Genes Dev (2009) 2.75
Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med (2003) 2.59
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol (2009) 2.47
Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc Natl Acad Sci U S A (2010) 2.43
Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res (2008) 2.35
Position-dependent alternative splicing activity revealed by global profiling of alternative splicing events regulated by PTB. Nat Struct Mol Biol (2010) 2.19
Effect of population and gender on chemotherapeutic agent-induced cytotoxicity. Mol Cancer Ther (2007) 2.05
Pharmacogenomic discovery using cell-based models. Pharmacol Rev (2009) 1.96
Identification of common genetic variants that account for transcript isoform variation between human populations. Hum Genet (2008) 1.96
A correlation with exon expression approach to identify cis-regulatory elements for tissue-specific alternative splicing. Nucleic Acids Res (2007) 1.94
Alternative splicing regulates mouse embryonic stem cell pluripotency and differentiation. Proc Natl Acad Sci U S A (2010) 1.93
Sensitive and specific single-molecule sequencing of 5-hydroxymethylcytosine. Nat Methods (2011) 1.90
ANOSVA: a statistical method for detecting splice variation from expression data. Bioinformatics (2005) 1.88
Exploring functional relationships between components of the gene expression machinery. Nat Struct Mol Biol (2005) 1.87
Exon-level microarray analyses identify alternative splicing programs in breast cancer. Mol Cancer Res (2010) 1.84
Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst (2010) 1.76
Mapping genes that contribute to daunorubicin-induced cytotoxicity. Cancer Res (2007) 1.73
The HapMap Resource is Providing New Insights into Ourselves and its Application to Pharmacogenomics. Bioinform Biol Insights (2008) 1.73
Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans. Mol Cancer Ther (2008) 1.67
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol (2005) 1.63
Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation. Pharmacogenomics (2012) 1.63
A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res (2005) 1.62
Human transcriptome array for high-throughput clinical studies. Proc Natl Acad Sci U S A (2011) 1.62
Somatic acquisition and signaling of TGFBR1*6A in cancer. JAMA (2005) 1.59
Interpretation of digital mammograms: comparison of speed and accuracy of soft-copy versus printed-film display. Radiology (2002) 1.59
Modeling kinetic rate variation in third generation DNA sequencing data to detect putative modifications to DNA bases. Genome Res (2012) 1.59
Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res (2008) 1.57
Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action. Biochem Pharmacol (2010) 1.52
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol (2002) 1.50
Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res (2009) 1.48
Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res (2011) 1.47
Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood (2008) 1.46